세계의 보조생식기술(ART) 시장 : 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The assisted reproductive technology market size generated USD 28.64 billion in 2025 and is forecast to advance to USD 40.56 billion by 2030, reflecting a 7.21% CAGR.

Adoption accelerates as artificial intelligence (AI) reaches 70-97% accuracy in embryo selection, improving clinical decisions while cutting laboratory workload. Private-equity capital flows underscore sector resilience, exemplified by Astorg's agreement to buy Hamilton Thorne at a 54% premium, signalling confidence in mission-critical laboratory platforms. Employer-sponsored fertility benefits now cover 40-42% of United States workers, broadening the paying patient pool and stabilising revenues for the assisted reproductive technology market. Regionally, Asia-Pacific's rapid clinic roll-out and China's fertility policy support drive the fastest growth, while Europe readies for the 2027 Regulation on Substances of Human Origin that will harmonise quality standards across borders.

Global Assisted Reproductive Technology (ART) Market Trends and Insights

Rising Global Infertility Prevalence

Female infertility in Asia-Pacific rose markedly, with polycystic ovary syndrome (PCOS) cited as a major driver. Demographic infertility in some Middle-Eastern countries stands at 38.5%, far above the 3.8% clinical infertility rate, indicating large latent demand. Lifestyle shifts-urban stress, dietary change, occupational toxins-further erode reproductive health across age groups. Policymakers increasingly frame infertility as a public-health issue requiring systematic intervention. Together, these factors sustain long-run volume growth for the assisted reproductive technology market.

Increasing Acceptance of Assisted Reproductive Procedures

Organised Indian clinic chains now capture 35-40% of national IVF cycles-up from zero 10 years ago-showing stigma decline and brand-led consolidation. All EU members fund IVF after Poland reinstated reimbursement in 2025, signalling pan-European support. U.S. companies promote fertility benefits to attract talent; 66% of employees weigh reproductive-health perks in job decisions. Visibility rises as LGBTQIA+ populations, single parents and celebrity advocates normalise usage. Societal openness drives patient inflows and stabilises payer mix for the assisted reproductive technology market.

High Treatment Costs and Limited Insurance Coverage

United States IVF averages USD 12,000-25,000 per cycle, with 2.5 cycles typically needed, thrusting many households above USD 30,000 in expenses. Only 21 U.S. states mandate partial infertility coverage, leaving sizeable gaps. Nearly 28% of employees entering treatment incur debt, disproportionately burdening marginalized groups. Internationally, cycle costs vary from EUR 4,000 in many EU states to higher levels in developed Asia, spurring outbound medical tourism that can fragment follow-up care. Without broader reimbursement, cost remains the steepest barrier to assisted reproductive technology market participation.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Technological Innovations in Reproductive Medicine
2. Growth of Cross-Border Fertility Services
3. Stringent and Evolving Regulatory Frameworks

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Instruments & Equipment generated 53.45% of 2024 revenue, underscoring laboratories' dependence on high-value capital assets for incubating, imaging and micromanipulating gametes. Software & AI Solutions will grow at 9.65% CAGR to 2030 as clinics chase predictive analytics that boost implantation odds. Vendors increasingly bundle microscopes with AI algorithms-such as EmbryoScope+ paired with iDAScore-to offer an integrated decision-support workflow. Automation pioneers including Conceivable Life Sciences deploy AURA, the first fully robotic IVF lab, processing 2,000 cycles a year while slashing headcount.

Recurring consumables remain crucial. Culture media sales track cycle volume because every retrieval triggers new batches, stabilising revenue even during downturns. Meanwhile, the assisted reproductive technology market size linked to laboratory service contracts is expanding as manufacturers introduce subscription models for continuous software updates and remote calibration. These hybrid hardware-software offerings deepen switching costs and create stickier cash flows, attracting private-equity capital.

Digitalisation also fosters data-sharing networks that feed machine-learning models, widening performance gaps between adopters and laggards. Clinics using AI allocation protocols have reported 13.6% higher success rates after chain acquisition due to standardised best practices. Over 2025-2030, product roadmaps show a clear pivot from stand-alone instruments toward cloud-enabled ecosystems that monetise both disposables and proprietary datasets.

In-Vitro Fertilisation preserved technological primacy with 64.34% 2024 share, benefiting from decades of know-how and broad reimbursements. Yet elective freeze-all strategies fuel a 9.57% CAGR for Frozen Embryo Replacement cycles, which allow chromosomal screening and flexible scheduling without hormone-related endometrial stress. Clinics report fewer multiple pregnancies after vitrification plus single-embryo transfer protocols-an increasingly mandated quality metric.

Emerging science reshapes the technology stack. Induced-pluripotent-stem-cell methods, exemplified by Fertilo, could lower ovarian stimulation exposure by 80% while compressing treatment duration to three days. Research into in-vitro gametogenesis hints at lab-grown gametes that may open new parenthood routes for severe male-factor or same-sex couples. For now, artificial insemination persists as a lower-complexity option but surrenders share to IVF variants as payers recognise higher overall success per investment.

Clinicians increasingly tailor technology bundles-combining vitrified embryos, PGT-A genetic testing and AI scoring-to patient-specific prognostics, reducing miscarriage risk while optimising cost per live birth. That personalisation further enlarges the assisted reproductive technology market as older patients consider treatment viable.

The Assisted Reproductive Technology Market Report is Segmented by Product & Service (Instruments & Equipment, and More), Technology (In-Vitro Fertilisation (IVF), and More), Procedure (Fresh Non-Donor, and More), End User (Fertility Clinics, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America controlled 45.43% of 2024 revenue, buoyed by premium pricing and rising employer benefits that absorb high cycle costs. The assisted reproductive technology market size in this region also reflects ongoing automation pilots and an ecosystem of software vendors clustered around biomedical corridors. U.S. reimbursement expansion through corporate plans continues to offset uneven state mandates, whereas Canada's single-payer system covers limited cycles, prompting some patients to seek private U.S. services and sustaining cross-border flows.

Asia-Pacific is projected to exhibit an 8.65% CAGR to 2030, the fastest among regions. India opens 60-70 new IVF facilities annually, with organised chains steadily capturing share through branded quality guarantees that appeal to price-sensitive urban couples. China's government promotes fertility following birth-rate declines, offering provincial subsidies and approving more clinic licences. The assisted reproductive technology market size for Asia-Pacific is forecast to reach USD 13.5 billion by 2028, supported by cost arbitrage that attracts foreign patients seeking both affordability and competent care.

Europe presents a mature yet evolving picture. Universal public funding after Poland's policy reversal in 2025 eliminates national gaps, yet waiting lists vary widely. Demographically, Europe's fertility rate of 1.46 births per woman remains below replacement, prolonging demand. The 2027 SoHO regulation will standardise quality metrics and traceability, potentially smoothing intra-EU patient redirection to high-capacity centers. Spain, Denmark and Belgium already host large volumes of foreign cycles, and shared EU data registries could enhance transparency and outcomes, reinforcing Europe's role in the assisted reproductive technology market.

1. The Cooper Companies
2. Vitrolife
3. FUJIFILM Irvine Scientific Inc.
4. Ferring Pharmaceuticals
5. Merck
6. Hamilton Thorne Ltd.
7. Thermo Fisher Scientific
8. Cook Group
9. Genea Biomedx
10. Bloom IVF Centre
11. Esco Lifesciences
12. Memmert
13. Laboratoire CCD
14. Nidacon International
15. Microm Ltd.
16. Progyny Inc.
17. Ovascience
18. CCRM Fertility
19. Igenomix
20. Gyntics Medical Products

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 A

2 Introduction

• 2.1 Study Assumptions & Market Definition
• 2.2 Scope of the Study

3 Research Methodology

4 Executive Summary

5 Market Landscape

• 5.1 Market Overview
• 5.2 Market Drivers
  • 5.2.1 Rising Global Infertility Prevalence
  • 5.2.2 Increasing Acceptance of Assisted Reproductive Procedures
  • 5.2.3 Rapid Technological Innovations in Reproductive Medicine
  • 5.2.4 Growth of Cross-Border Fertility Services
  • 5.2.5 Integration of Artificial Intelligence in Embryo Selection
  • 5.2.6 Expansion of Employer-Sponsored Fertility Benefits
• 5.3 Market Restraints
  • 5.3.1 High Treatment Costs and Limited Insurance Coverage
  • 5.3.2 Stringent and Evolving Regulatory Frameworks
  • 5.3.3 Ethical And Religious Concerns Regarding Embryo Manipulation
  • 5.3.4 Clinical Variability and Uncertain Success Rates
• 5.4 Regulatory Landscape
• 5.5 Porter's Five Forces Analysis
  • 5.5.1 Threat Of New Entrants
  • 5.5.2 Bargaining Power Of Buyers
  • 5.5.3 Bargaining Power Of Suppliers
  • 5.5.4 Threat Of Substitutes
  • 5.5.5 Competitive Rivalry

6 Market Size & Growth Forecasts (Value, USD)

• 6.1 By Product & Service
  • 6.1.1 Instruments & Equipment
  • 6.1.2 Reagents & Media
  • 6.1.3 Software & AI Solutions
• 6.2 By Technology
  • 6.2.1 In-Vitro Fertilisation (IVF)
  • 6.2.2 Artificial Insemination (AI-IUI)
  • 6.2.3 Frozen Embryo Replacement (FER)
  • 6.2.4 Other Technology
• 6.3 By Procedure
  • 6.3.1 Fresh Non-Donor
  • 6.3.2 Fresh Donor
  • 6.3.3 Frozen Donor
  • 6.3.4 Frozen Non-Donor
• 6.4 By End User
  • 6.4.1 Fertility Clinics
  • 6.4.2 Hospitals & Surgical Centres
  • 6.4.3 Cryobanks & Research Institutes
• 6.5 Geography
  • 6.5.1 North America
    • 6.5.1.1 United States
    • 6.5.1.2 Canada
    • 6.5.1.3 Mexico
  • 6.5.2 Europe
    • 6.5.2.1 Germany
    • 6.5.2.2 United Kingdom
    • 6.5.2.3 France
    • 6.5.2.4 Italy
    • 6.5.2.5 Spain
    • 6.5.2.6 Rest of Europe
  • 6.5.3 Asia-Pacific
    • 6.5.3.1 China
    • 6.5.3.2 Japan
    • 6.5.3.3 India
    • 6.5.3.4 Australia
    • 6.5.3.5 South Korea
    • 6.5.3.6 Rest of Asia-Pacific
  • 6.5.4 Middle East & Africa
    • 6.5.4.1 GCC
    • 6.5.4.2 South Africa
    • 6.5.4.3 Rest of Middle East & Africa
  • 6.5.5 South America
    • 6.5.5.1 Brazil
    • 6.5.5.2 Argentina
    • 6.5.5.3 Rest of South America

7 Competitive Landscape

• 7.1 Market Concentration
• 7.2 Market Share Analysis
• 7.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
  • 7.3.1 CooperSurgical Inc.
  • 7.3.2 Vitrolife AB
  • 7.3.3 FUJIFILM Irvine Scientific Inc.
  • 7.3.4 Ferring B.V.
  • 7.3.5 Merck KGaA (EMD Serono)
  • 7.3.6 Hamilton Thorne Ltd.
  • 7.3.7 Thermo Fisher Scientific Inc.
  • 7.3.8 Cook Medical Inc.
  • 7.3.9 Genea Biomedx
  • 7.3.10 Bloom IVF Centre
  • 7.3.11 Esco Medical
  • 7.3.12 Memmert GmbH + Co.KG
  • 7.3.13 Laboratoire CCD
  • 7.3.14 Nidacon International AB
  • 7.3.15 Microm Ltd.
  • 7.3.16 Progyny Inc.
  • 7.3.17 OvaScience Inc.
  • 7.3.18 CCRM Fertility
  • 7.3.19 Igenomix
  • 7.3.20 Gyntics Medical Products

8 Market Opportunities & Future Outlook

• 8.1 White-Space & Unmet-Need Assessment